Research ExplorerPublicationsReduced intensity-conditioned allogeneic stem cell transplan...

Reduced intensity-conditioned allogeneic stem cell transplantation for multiple myeloma relapsing or progressing after autologous Transplantation: a study by the European Group for Blood and Marrow Transplantation

Standard

Reduced intensity-conditioned allogeneic stem cell transplantation for multiple myeloma relapsing or progressing after autologous Transplantation: a study by the European Group for Blood and Marrow Transplantation. / Auner, H W; Szydlo, R; van Biezen, A; Iacobelli, S; Gahrton, G; Milpied, N; Volin, L; Janssen, J; Nguyen Quoc, S; Michallet, M; Schoemans, H; El Cheikh, J; Petersen, E; Guilhot, F; Schönland, S; Ahlberg, L; Morris, C; Garderet, L; de Witte, T; Kröger, N; Plasma Cell Dyscrasia Sub-committee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation (EBMT).

In: BONE MARROW TRANSPL, Vol. 48, No. 11, 01.11.2013, p. 1395-400.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Auner, HW, Szydlo, R, van Biezen, A, Iacobelli, S, Gahrton, G, Milpied, N, Volin, L, Janssen, J, Nguyen Quoc, S, Michallet, M, Schoemans, H, El Cheikh, J, Petersen, E, Guilhot, F, Schönland, S, Ahlberg, L, Morris, C, Garderet, L, de Witte, T, Kröger, N & Plasma Cell Dyscrasia Sub-committee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation (EBMT) 2013, 'Reduced intensity-conditioned allogeneic stem cell transplantation for multiple myeloma relapsing or progressing after autologous Transplantation: a study by the European Group for Blood and Marrow Transplantation', BONE MARROW TRANSPL, vol. 48, no. 11, pp. 1395-400. https://doi.org/10.1038/bmt.2013.73

APA

Auner, H. W., Szydlo, R., van Biezen, A., Iacobelli, S., Gahrton, G., Milpied, N., Volin, L., Janssen, J., Nguyen Quoc, S., Michallet, M., Schoemans, H., El Cheikh, J., Petersen, E., Guilhot, F., Schönland, S., Ahlberg, L., Morris, C., Garderet, L., de Witte, T., ... Plasma Cell Dyscrasia Sub-committee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation (EBMT) (2013). Reduced intensity-conditioned allogeneic stem cell transplantation for multiple myeloma relapsing or progressing after autologous Transplantation: a study by the European Group for Blood and Marrow Transplantation. BONE MARROW TRANSPL, 48(11), 1395-400. https://doi.org/10.1038/bmt.2013.73

Vancouver

Auner HW, Szydlo R, van Biezen A, Iacobelli S, Gahrton G, Milpied N et al. Reduced intensity-conditioned allogeneic stem cell transplantation for multiple myeloma relapsing or progressing after autologous Transplantation: a study by the European Group for Blood and Marrow Transplantation. BONE MARROW TRANSPL. 2013 Nov 1;48(11):1395-400. https://doi.org/10.1038/bmt.2013.73

Bibtex

@article{78ea5caf51964cea80f80b3e84b21992,
title = "Reduced intensity-conditioned allogeneic stem cell transplantation for multiple myeloma relapsing or progressing after autologous Transplantation: a study by the European Group for Blood and Marrow Transplantation",
abstract = "Outcomes and prognostic factors of reduced intensity-conditioned allo-SCT (RIC allo-SCT) for multiple myeloma (MM) relapsing or progressing after prior autologous (auto)-SCT are not well defined. We performed an analysis of 413 MM patients who received a related or unrelated RIC allo-SCT for the treatment of relapse/progression after prior auto-SCT. Median age at RIC allo-SCT was 54.1 years, and 44.6% of patients had undergone two or more prior auto-SCTs. Median OS and PFS from the time of RIC allo-SCT for the entire population were 24.7 and 9.6 months, respectively. Cumulative non-relapse mortality (NRM) at 1 year was 21.5%. In multivariate analysis, CMV seronegativity of both patient and donor was associated with significantly better PFS, OS and NRM. Patient-donor gender mismatch was associated with better PFS, fewer than two prior auto-SCT was associated with better OS, and shorter time from the first auto-SCT to the RIC allo-SCT was associated with lower NRM. The results of this study identify patient and donor CMV seronegativity as the key prognostic factor for outcome after RIC allo-SCT for MM relapsing or progressing after prior auto-SCT.",
keywords = "Adult, Aged, Female, Hematopoietic Stem Cell Transplantation, Humans, Male, Middle Aged, Multiple Myeloma, Prognosis, Recurrence, Treatment Outcome, Young Adult",
author = "Auner, {H W} and R Szydlo and {van Biezen}, A and S Iacobelli and G Gahrton and N Milpied and L Volin and J Janssen and {Nguyen Quoc}, S and M Michallet and H Schoemans and {El Cheikh}, J and E Petersen and F Guilhot and S Sch{\"o}nland and L Ahlberg and C Morris and L Garderet and {de Witte}, T and N Kr{\"o}ger and {Plasma Cell Dyscrasia Sub-committee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation (EBMT)}",
year = "2013",
month = nov,
day = "1",
doi = "10.1038/bmt.2013.73",
language = "English",
volume = "48",
pages = "1395--400",
journal = "BONE MARROW TRANSPL",
issn = "0268-3369",
publisher = "NATURE PUBLISHING GROUP",
number = "11",

}

RIS

TY - JOUR

T1 - Reduced intensity-conditioned allogeneic stem cell transplantation for multiple myeloma relapsing or progressing after autologous Transplantation: a study by the European Group for Blood and Marrow Transplantation

AU - Auner, H W

AU - Szydlo, R

AU - van Biezen, A

AU - Iacobelli, S

AU - Gahrton, G

AU - Milpied, N

AU - Volin, L

AU - Janssen, J

AU - Nguyen Quoc, S

AU - Michallet, M

AU - Schoemans, H

AU - El Cheikh, J

AU - Petersen, E

AU - Guilhot, F

AU - Schönland, S

AU - Ahlberg, L

AU - Morris, C

AU - Garderet, L

AU - de Witte, T

AU - Kröger, N

AU - Plasma Cell Dyscrasia Sub-committee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation (EBMT)

PY - 2013/11/1

Y1 - 2013/11/1

N2 - Outcomes and prognostic factors of reduced intensity-conditioned allo-SCT (RIC allo-SCT) for multiple myeloma (MM) relapsing or progressing after prior autologous (auto)-SCT are not well defined. We performed an analysis of 413 MM patients who received a related or unrelated RIC allo-SCT for the treatment of relapse/progression after prior auto-SCT. Median age at RIC allo-SCT was 54.1 years, and 44.6% of patients had undergone two or more prior auto-SCTs. Median OS and PFS from the time of RIC allo-SCT for the entire population were 24.7 and 9.6 months, respectively. Cumulative non-relapse mortality (NRM) at 1 year was 21.5%. In multivariate analysis, CMV seronegativity of both patient and donor was associated with significantly better PFS, OS and NRM. Patient-donor gender mismatch was associated with better PFS, fewer than two prior auto-SCT was associated with better OS, and shorter time from the first auto-SCT to the RIC allo-SCT was associated with lower NRM. The results of this study identify patient and donor CMV seronegativity as the key prognostic factor for outcome after RIC allo-SCT for MM relapsing or progressing after prior auto-SCT.

AB - Outcomes and prognostic factors of reduced intensity-conditioned allo-SCT (RIC allo-SCT) for multiple myeloma (MM) relapsing or progressing after prior autologous (auto)-SCT are not well defined. We performed an analysis of 413 MM patients who received a related or unrelated RIC allo-SCT for the treatment of relapse/progression after prior auto-SCT. Median age at RIC allo-SCT was 54.1 years, and 44.6% of patients had undergone two or more prior auto-SCTs. Median OS and PFS from the time of RIC allo-SCT for the entire population were 24.7 and 9.6 months, respectively. Cumulative non-relapse mortality (NRM) at 1 year was 21.5%. In multivariate analysis, CMV seronegativity of both patient and donor was associated with significantly better PFS, OS and NRM. Patient-donor gender mismatch was associated with better PFS, fewer than two prior auto-SCT was associated with better OS, and shorter time from the first auto-SCT to the RIC allo-SCT was associated with lower NRM. The results of this study identify patient and donor CMV seronegativity as the key prognostic factor for outcome after RIC allo-SCT for MM relapsing or progressing after prior auto-SCT.

KW - Adult

KW - Aged

KW - Female

KW - Hematopoietic Stem Cell Transplantation

KW - Humans

KW - Male

KW - Middle Aged

KW - Multiple Myeloma

KW - Prognosis

KW - Recurrence

KW - Treatment Outcome

KW - Young Adult

U2 - 10.1038/bmt.2013.73

DO - 10.1038/bmt.2013.73

M3 - SCORING: Journal article

C2 - 23708704

VL - 48

SP - 1395

EP - 1400

JO - BONE MARROW TRANSPL

JF - BONE MARROW TRANSPL

SN - 0268-3369

IS - 11

ER -